Key result
Telmisartan demonstrates potent antihypertensive, cardioprotective, and nephroprotective properties while acting as a PPAR gamma agonist to correct metabolic profiles in systemic hypertension patients.
Why the study?
Does telmisartan reduce cardiovascular risk and improve metabolic profiles in patients with systemic hypertension?
Does telmisartan reduce cardiovascular risk and improve metabolic profiles in patients with systemic hypertension?
Telmisartan offers comprehensive cardiovascular risk reduction in hypertensive patients by effectively lowering blood pressure and improving metabolic parameters.
Telmisartan may support metabolic benefits in hypertension; leaves open need for RCTs to confirm CV outcomes.
The article is focused on the issues of clinical efficacy of telmisartan — angiotensin II type 1 receptor blocker from the perspective of its influence on cardiovascular risk in systemic hypertension patients. The results presented, of a variety of studies, witnessing potent antihypertensive and protective properties of telmisartan. The opportunities described, for usage of the drug in high risk patients, its efficacy in cardio- and nephroprotection. Special attention is paid for an exclusive property of telmisartan to be an agonist of PPAR γ-receptors, hence to correct glucose and lipid metabolism in patients with metabolic syndrome and diabetes.
No takes yet. Share an insight, caveat, or question.
Остроумова et al. (2018) conducted a review in Systemic hypertension. Telmisartan was evaluated. Telmisartan demonstrates potent antihypertensive, cardioprotective, and nephroprotective properties while acting as a PPAR gamma agonist to correct metabolic profiles in systemic hypertension patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: